Download PDF
Thromb Haemost 1999; 82(02): 377-384
DOI: 10.1055/s-0037-1615856
Research Article
Schattauer GmbH

Thrombopoietin-Induced Signal Transduction and Potentiation of Platelet Activation

Atsushi Oda
1   Hokkaido Red Cross Blood Center, Keio University, Tokyo
,
Yoshitaka Miyakawa
2   Division of Hematology, Department of Internal Medicine, Keio University, Tokyo
,
Brian J. Druker
5   Division of Hematology and Medical Oncology, Oregon Health, OR, USA
,
Katsutoshi Ozaki
2   Division of Hematology, Department of Internal Medicine, Keio University, Tokyo
,
Hideya Ohashi
4   Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, JAPAN
,
Takashi Kato
4   Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, JAPAN
,
Hiroshi Miyazaki
4   Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, JAPAN
,
Makoto Handa
5   Division of Hematology and Medical Oncology, Oregon Health, OR, USA
,
Kenji Ikebuchi
1   Hokkaido Red Cross Blood Center, Keio University, Tokyo
,
Yasuo Ikeda
2   Division of Hematology, Department of Internal Medicine, Keio University, Tokyo
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

The presence of thrombopoietin, a humoral regulator of megakaryopoiesis and thrombopoiesis, had been suggested for years,1 however, some investigators were skeptical about the existence of such a factor. Modern studies of thrombopoietin begin with the cloning of c-mpl (the cellular counterpart of the v-mpl oncogene) and its cognate ligand genes. Following the cloning of the c-mpl proto-oncogene,2 Methia et al3 found that, in the presence of oligonucleotides antisense to the gene, CD34+ cells developed into megakaryocytic precursors less efficiently. As the development into other lineage was nearly intact, it was reasonably argued that the c-mpl protein may be the receptor for a thrombopoietin-like factor.3 This study inspired numerous investigations, which culminated in the cloning of the thrombopoietin gene in 1994.1, 4-8

 

  • References

  • 1 Kelemen E. Specific thrombopoietin cloned and sequenced— with personal retrospect and clinical prospects. Leukemia 1995; 9: 1-2.
    PubMedGoogle Scholar
  • 2 Skoda RC, Seldin DC, Chiang MK, Peichel CL, Vogt TF. Leder. Murine c-mpl: A member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J 1993; 12: 2645-2653.
    PubMedGoogle Scholar
  • 3 Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395-1401.
    PubMedGoogle Scholar
  • 4 Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339: 746-754.
    CrossrefPubMedGoogle Scholar
  • 5 Kuter DJ. Thrombopoietins and thrombopoiesis: A clinical perspective. Vox Sang 1998; 74 (Suppl. 02) 75-85.
    CrossrefPubMedGoogle Scholar
  • 6 Kato T, Matsumoto A, Ogami K, Tahara T, Morita H, Miyazaki H. Native thrombopoietin: Structure and function. Stem Cells 1998; 16: 322-328.
    CrossrefPubMedGoogle Scholar
  • 7 Wendling F, Vainchenker W. Thrombopoietin and its receptor. Eur Cytokine Netw 1998; 9: 221-231.
    PubMedGoogle Scholar
  • 8 Souyri M. Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin. Semin Hematol 1998; 35: 222-231.
    PubMedGoogle Scholar
  • 9 Ku H, Hirayama F, Kato T, Miyazaki H, Aritomi M, Ota Y, D’Andrea AD, Lyman SD, Ogawa M. Soluble thrombopoietin receptor (Mpl) and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand for Flt3/Flk2. Blood 1996; 88: 4124-4131.
    PubMedGoogle Scholar
  • 10 Taksin AL, Couedic JPL, Dusanter-Fourt I, Masse A, Giraudier S, Katz A, Wendling F, Vainchenker W, Casadevall N, Debili N. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93: 125-139.
    PubMedGoogle Scholar
  • 11 Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92: 3234-3238.
    CrossrefPubMedGoogle Scholar
  • 12 Kitamura T, Onishi M, Yahata T, Kanakura Y, Asano S. Activating mutations of the transmembrane domain of MPL in vitro and in vivo: incorrect sequence of MPL-K, an alternative spliced form of MPL. Blood 1998; 92: 2596-2597.
    PubMedGoogle Scholar
  • 13 Brizzi MF, Battaglia E, Rosso A, Strippoli P, Montrucchio G, Camussi G, Pegoraro L. Regulation of polymorphonuclear cell activation by thrombopoietin. J Clin Invest 1997; 99: 1576-1584.
    CrossrefPubMedGoogle Scholar
  • 14 Kato T, Oda A, Inagaki Y, Ohashi H, Matsumoto A, Ozaki K, Miyakawa Y, Watarai H, Fuju K, Kokubo A, Kadoya T, Ikeda Y, Miyazaki H. Thrombin cleaves recombinant human thrombopoietin: one of the proteolytic events that generates truncated forms of thrombopoietin. Proc Natl Acad Sci USA 1997; 94: 4669-4674.
    CrossrefPubMedGoogle Scholar
  • 15 Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486-4592.
    PubMedGoogle Scholar
  • 16 Oda A, Ozaki K, Druker BJ, Miyakawa Y, Miyazaki H, Handa M, Morita H, Ohashi H, Ikeda Y. P120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin. Blood 1996; 88: 1330-1338.
    PubMedGoogle Scholar
  • 17 Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari DP, Wrighton NC, Barrett RW, Dower WJ. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276: 1696-1699.
    CrossrefPubMedGoogle Scholar
  • 18 Lalau Keraly C, Kinlough-Rathbone RL, Packham MA, Suzuki H, Mustard JF. Conditions affecting the responses of human platelets to epinephrine. Thromb Haemost 1988; 60: 209-216.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664-4670.
    PubMedGoogle Scholar
  • 20 Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Letts 1995; 374: 48-52.
    CrossrefPubMedGoogle Scholar
  • 21 Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, Ikeda Y. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996; 87: 439-446.
    PubMedGoogle Scholar
  • 22 Livnah O, Stura EA, Middleton SA, Johson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283: 987-990.
    CrossrefPubMedGoogle Scholar
  • 23 Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445-1457.
    CrossrefPubMedGoogle Scholar
  • 24 de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183: 651-656.
    CrossrefPubMedGoogle Scholar
  • 25 Gainsford T, Roberts AW, Kimura S, Metcalf D, Dranoff G, Mulligan RC, Begley CG, Robb L, Alexander WS. Cytokine production and function in c-mpl-deficient mice: No physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood 1998; 91: 2745-2752.
    PubMedGoogle Scholar
  • 26 Muraoka K, Ishii E, Tsuji K, Yamamoto S, Yamaguchi H, Hara T, Koga H, Nakahata T, Miyazaki S. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 1997; 96: 287-292.
    CrossrefPubMedGoogle Scholar
  • 27 Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999; 96: 3132-3136.
    CrossrefPubMedGoogle Scholar
  • 28 Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998; 18: 49-52.
    CrossrefPubMedGoogle Scholar
  • 29 Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi M, Hosokawa M, Asaka M. Familial essential thrombocythemia associated with one-base deletion in the 5’-untranslated region of the thrombopoietin gene. Blood 1998; 92: 1091-1096.
    PubMedGoogle Scholar
  • 30 Komura-Naito E, Matsumura T, Sawada T, Kato T, Tahara T. Thrombopoietin in patients with hepatoblastoma. Blood 1997; 90: 2849-2850.
    PubMedGoogle Scholar
  • 31 Yamaguchi H, Ishii E, Hayashida Y, Hirata Y, Sakai R, Miyazaki S. Mechanism of thrombocytosis in hepatoblastoma: A case report. Pediatr Hematol Oncol 1996; 13: 539-544.
    CrossrefPubMedGoogle Scholar
  • 32 Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-395.
    CrossrefPubMedGoogle Scholar
  • 33 Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: Functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA 1997; 94: 2350-2355.
    CrossrefPubMedGoogle Scholar
  • 34 Morita H, Tahara T, Matsumoto A, Kato T, Miyazaki H, Ohashi H. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Letts 1996; 395: 228-234.
    CrossrefPubMedGoogle Scholar
  • 35 Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol 1997; 17: 4991-5000.
    CrossrefPubMedGoogle Scholar
  • 36 Hill RJ, Zozulya S, Lu YL, Hollenbach PW, Joyce-Shaikh B, Bogenberger J, Gishizky ML. Differentiation induced by the c-mpl cytokine receptor is blocked by mutant Shc adaptor protein. Cell Growth Differ 1996; 7: 1125-1134.
    PubMedGoogle Scholar
  • 37 Zauli G, Gibellini D, Vitale M, Secchiero P, Celeghini C, Bassini A, Pierpaoli S, Marchisio M, Guidotti L, Capitani S. The induction of megakaryocyte differentiation is accompanied by selective Ser133 phosphorylation of the transcription factor CREB in both HEL cell line and primary CD34+ cells. Blood 1998; 92: 472-480.
    PubMedGoogle Scholar
  • 38 Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA 1995; 92: 5292-5296.
    CrossrefPubMedGoogle Scholar
  • 39 Takatoku M, Kametaka M, Shimizu R, Miura Y, Komatsu N. Identification of functional domains of the human thrombopoietin receptor required for growth and differentiation of megakaryocytic cells. J Biol Chem 1997; 272: 7259-7263.
    CrossrefPubMedGoogle Scholar
  • 40 Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-mpl ligand, thrombopoietin. Blood 1995; 86: 4054-4062.
    PubMedGoogle Scholar
  • 41 Rodriguez-Linares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J 1996; 316: 93-98.
    CrossrefPubMedGoogle Scholar
  • 42 Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541-1545.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762-2768.
    PubMedGoogle Scholar
  • 44 Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, Ikeda Y. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995; 86: 23-27.
    PubMedGoogle Scholar
  • 45 Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S, Ikeda Y. Crkl is constitutively tyrosine-phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996; 88: 4304-4313.
    PubMedGoogle Scholar
  • 46 Miyakawa Y, Oda A, Druker BJ, Ozaki K, Handa M, Ohashi H, Ikeda Y. Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets. Blood 1997; 89: 2789-2798.
    PubMedGoogle Scholar
  • 47 Ozaki K, Oda A, Wakao H, Rhodes J, Druker BJ, Ishida A, Wakui M, Okamoto S, Morita K, Handa M, Komatsu N, Ohashi H, Miyajima A, Ikeda Y. Thrombopoietin induces association of crkl with STAT5 but not STAT3 in human platelets. Blood 1998; 92: 4652-4662.
    PubMedGoogle Scholar
  • 48 Oda A, Sawada K, Druker BJ, Ozaki K, Takano H, Koizumi K, Fukada Y, Handa M, Koike T, Ikeda Y. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors. Blood 1998; 92: 443-451.
    PubMedGoogle Scholar
  • 49 Rhodes J, York RD, Tajinda K, Tara D, Druker BJ. Analysis of Crkl and STAT5 interaction in BCR-ABL expressing cells. Blood 1998; 92 (Suppl. 01) 476a.
    PubMedGoogle Scholar
  • 50 Ballmaier M, Schulze H, Strauss G, Cherkaoui K, Wittner N, Lynen S, Wolters S, Bogenberger J, Welte K. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: Elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997; 90: 612-619.
    PubMedGoogle Scholar
  • 51 Strippoli P, Savoia A, Iolascon A, Tonelli R, Savino M, Giordano P, D’Avanzo M, Massolo F, Locatelli F, Borgna C, De Mattia D, Zelante L, Paolucci G, Bagnara GP. Mutational screening of thrombopoietin receptor gene (c-mpl) in patients with congenital thrombocytopenia and absent radii. Br J Haematol 1998; 103: 311-314.
    CrossrefPubMedGoogle Scholar
  • 52 Sekine I, Hagiwara T, Miyazaki H, Hirayama K, Dobashi H, Kogawa K, Yoshioka S. Thrombocytopenia with absent radii syndrome: Studies on serum thrombopoietin levels and megakaryopoiesis in vitro. J Pediatr Hematol Oncol 1998; 20: 74-78.
    CrossrefPubMedGoogle Scholar
  • 53 Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S, Kato T, Miyazaki H, Tomiyama Y, Kurata Y, Matsuzawa Y, Kanakura Y. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031-4038.
    PubMedGoogle Scholar
  • 54 Li J, Xia Y, Kuter DJ. Analysis of the thrombopoietin receptor (MPL) on patients from normal and essential thrombocythemic (ET) patients. Blood 1996; 88: 545a.
    PubMedGoogle Scholar
  • 55 Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338: 572-580.
    CrossrefPubMedGoogle Scholar
  • 56 Drachman JG, Sabath DF, Fox NE, Kaushansky K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 1997; 89: 483-492.
    CrossrefPubMedGoogle Scholar
  • 57 Ziegler S, de Sauvage FJ, Skoda RC. Transgenic rescue of the mpl knockout with mpl tyrosine mutants. Blood 1998; 92 (Suppl. 01) 713a.
    PubMedGoogle Scholar
  • 58 de Sauvage FJ, Lipari T, Steinmetz H, Blunting S, Jackson CW, Luoh S-M. Activation of the MAPK pathway is not required for platelet production in vivo. Blood 1998; 92 (Suppl. 01) 713a.
    PubMedGoogle Scholar
  • 59 Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15: 797-819.
    CrossrefPubMedGoogle Scholar
  • 60 Stoffel R, Ziegler S, Ghilardi N, Ledermann B, de Sauvage FJ, Skoda RC. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci USA 1999; 96: 698-702.
    CrossrefPubMedGoogle Scholar
  • 61 Cantrell D. The real LAT steps forward. Trends Cell Biol 1998; 8: 180-182.
    CrossrefPubMedGoogle Scholar
  • 62 Gibbins JM, Briddon S, Shutes A, van Vugt MJ, van de Winkel JGJ, Saito T, Watson SP. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem 1998; 273: 34437-34443.
    CrossrefPubMedGoogle Scholar
  • 63 Saci A, Pain S, Rendu F, Bachelot-Loza C. Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves p120(Cbl). J Biol Chem 1999; 274: 1898-1904.
    CrossrefPubMedGoogle Scholar
  • 64 Miranti CK, Leng L, Maschberger P, Brugge JS, Shattil SJ. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1. Curr Biol 1998; 8: 1289-1299.
    CrossrefPubMedGoogle Scholar
  • 65 Sarkar S. Tyrosine phosphorylation and translocation of LAT in platelets. FEBS Lett 1998; 441: 357-360.
    CrossrefPubMedGoogle Scholar
  • 66 Duprez V, Blank U, Chretien S, Gisselbrecht S, Mayeux P. Physical and functional interaction between p72(syk) and erythropoietin receptor. J Biol Chem 1998; 273: 33985-33990.
    CrossrefPubMedGoogle Scholar
  • 67 Rittenhouse SE. Phosphoinositide 3-kinase activation and platelet function. Blood 1996; 88 (12) 4401-4414.
    PubMedGoogle Scholar
  • 68 O’Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O’Byrne J, Green MD, Fox RM, Berndt MC, Begley CG. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88: 3288-3298.
    PubMedGoogle Scholar